Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine/Clofarabine/Busulfan Conditioning for Lymphoma
NCT01701986Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Oct 2012
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of gemcitabine in B-cell non-Hodgkin lymphoma (B-NHL), non-Hodgkin lymphoma, T-cell, Hodgkin lymphoma (HL), sponsored by University of Texas MD Anderson Cancer Center. Started Oct 2012; status: completed.
02
Drugs
gemcitabine
03
Conditions
B-cell non-Hodgkin lymphoma (B-NHL)non-Hodgkin lymphoma, T-cellHodgkin lymphoma (HL)
Beyond the preview
Go deeper on NCT01701986.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01701986.